Skip to content
SearchContact UsDirectionsHome
Whitehead Institute for Biomedical Research
About WhiteheadFaculty and ResearchResearch NewsPublic ProgramsCareer OpportunitiesSupport Whitehead
Research News
Search News Archives

On Topic

Paradigm Magazine

Discovery Newsletter

Fact Sheets

Video Gallery

Podcast

For the News Media

whitehead home > research news > search news archives > 2004 news stories > battle over biodefense > banned in boston

Banned in Boston

For Mark Klempner, the infectious-diseases facility planned for Boston University Medical Center is “a dream come true.” But for some local citizen activists and scientists, the big lab isn’t a dream but a nightmare—right in the middle of Boston’s densely populated South End.

As currently planned, the National Emerging Infectious Diseases Laboratories will be located in a nine-story building with 223,000 square feet of space, about a fifth larger than Whitehead’s headquarters. Housing research on anthrax, plague, and other dangerous disease agents, the $178 million structure will be among the most “cautiously designed and onstructed types of buildings in the world,” Boston University officials stress. It will hold its own ventilation, electrical, decontamination, and waste disposal systems plus a state-of-the-art security system.

And the lab will aim purely at advancing basic science, says Klempner, shown here at the proposed site. “Emerging infectious diseases are one of the highest-priority areas for research around the world,” he says. “This is money incredibly well spent.”

But the plan upsets many in the Boston community. In September 2003, the citizen action group Alternatives for Community & Environment (or ACE) served notice that it was bringing suit against the project for “flagrant violations” of the Massachusetts Environmental Policy Act. In March of this year, ACE and another community group, Safety Net, sent a letter to the National Institutes of Health detailing a series of environmental and safety objections to the planned new biodefense lab. They argued that the facility “would likely constitute an appealing terrorist target because the patho-gens located inside could be used for bioweapons and could decimate large human population centers.”

Some scientists in the Boston metropolitan area also vigorously oppose the project, among them David Ozonoff, a professor of environmental health at Boston University School of Public Health. Although Ozonoff initially supported the facility, he changed his mind. “I became convinced that it was not serving the public health agenda,” he says, adding that he believes the project is “part of a process that was harming public health.”

“We have been very clear that this is entirely about public health–related matters,” Klempner responds. “All of the research will be public health–related, and there won’t be any that will be related to weapons in any way.”

“We’re trying to provide as much detailed information as possible about the safety and environmental impact of this laboratory,” he adds.

If the university fares well in regulatory processes, groundbreaking could come by next summer.

Written by freelance writer Barton Reppert, who writes about science and technology from his home in Gaithersburg, Maryland. This article first appeared in the Fall 2004 issue of Paradigm.

Whitehead Institute for Biomedical Research is a nonprofit, independent research and educational institution. Wholly independent in its governance, finances and research programs, Whitehead shares a close affiliation with the Massachusetts Institute of Technology through its faculty, who hold joint MIT appointments.

Photo: Richard Howard

CONTACT

Communications and Public Affairs
Phone: 617-258-5183
Email: newsroom@wi.mit.edu
Whitehead Institute contact information